RESUMO
Psoriasis is a chronic inflammatory skin disease characterized by thickening the epidermis with erythema, scaling, and proliferation. Noscapine (NOS) has several anti-inflammatory, anti-angiogenic, and anti-fibrotic effects, but its low solubility and large size results in its lower efficacy in the clinic. In this regard, solid lipid nanoparticles (SLN) encapsulated NOS (SLN-NOS) were fabricated using the well-known response surface method based on the central composite design and modified high-shear homogenization and ultrasound method. As a result, Precirol® was selected as the best lipid base for the SLN formulation based on Hildebrand-Hansen solubility parameters, in which SLN-NOS 1 % had the best zeta potential (-35.74 ± 2.59 mV), average particle size (245.66 ± 17 nm), polydispersity index (PDI, 0.226 ± 0.09), high entrapment efficiency (89.77 %), and ICH-based stability results. After 72 h, the SLN-NOS 1 % released 83.23 % and 58.49 % of the NOS at pH 5.8 and 7.4, respectively. Moreover, Franz diffusion cell's results indicated that the skin levels of NOS for SLN and cream formulations were 46.88 % and 13.5 % of the total amount, respectively. Our pharmacological assessments revealed that treatment with SLN-NOS 1 % significantly attenuated clinical parameters, namely ear thickness, length, and psoriasis area and severity index, compared to the IMQ group. Interestingly, SLN-NOS 1 % reduced the levels of interleukin (IL)-17, tumor necrosis factor-α, and transforming growth factor-ß, while elevating IL-10, compared to the IMQ group. Histology studies also showed that topical application of SLN-NOS 1 % significantly decreased parakeratosis, hyperkeratosis, acanthosis, and inflammation compared to the IMQ group. Taken together, SLN-NOS 1 % showed a high potential to attenuate skin inflammation.
Assuntos
Nanopartículas , Noscapina , Psoríase , Humanos , Imiquimode/farmacologia , Noscapina/farmacologia , Lipídeos/química , Pele , Psoríase/induzido quimicamente , Psoríase/tratamento farmacológico , Inflamação/tratamento farmacológicoAssuntos
Antineoplásicos/uso terapêutico , Doenças Palpebrais/diagnóstico , Doenças do Cabelo/diagnóstico , Imiquimode/uso terapêutico , Ceratose/diagnóstico , Ceratose/tratamento farmacológico , Idoso , Dermoscopia , Doenças Palpebrais/tratamento farmacológico , Doenças do Cabelo/tratamento farmacológico , Folículo Piloso , Humanos , MasculinoAssuntos
Antineoplásicos/administração & dosagem , Carcinoma Basocelular/terapia , Pavilhão Auricular , Neoplasias da Orelha/terapia , Imiquimode/administração & dosagem , Neoplasias Cutâneas/terapia , Administração Tópica , Carcinoma Basocelular/patologia , Quimioterapia Adjuvante , Cartilagem da Orelha , Neoplasias da Orelha/patologia , Humanos , Terapia Neoadjuvante , Neoplasias Cutâneas/patologiaRESUMO
Xeroderma pigmentosum is a rare hereditary autosomal recessive genodermatosis. At present, there are many treatment options for xeroderma pigmentosum, covering medical/procedural, surgical and combined modalities. However, the quality of these interventions has not been assessed. Our study aimed to perform a systematic review of the literature regarding the treatment of xeroderma pigmentosum. Multiple medical databases were accessed with the Medical Subject Headings terms; "xeroderma pigmentosum," "therapeutics" and "surgical procedures, operative" from January 2000 to April 2019, including articles published in Portuguese, Spanish and English (PROSPERO-CRD42018114858). Two hundred and ninety-eight studies were found in the databases researched, of which, after applying the inclusion criteria, only 33 studies remained. The 33 complete articles were read by three of the authors, having been found: 16 reported medical/procedural and 17 reported surgical treatments. Only one clinical study presented a good level of evidence (EL: 2): a randomized clinical trial using a T4 endonuclease V (T4N5) liposome lotion which reduced the development of skin lesions in patients with xeroderma pigmentosum. Amongst surgical modalities, all studies presented low evidence level (EL: 4). Three illustrative cases are also presented, to emphasize the multiple number of times that surgical modalities may be required in these patients. The therapeutic modalities, both clinical and surgical, for xeroderma pigmentosum presented a low level of scientific evidence which did not allow meta-analysis. More therapeutic studies, both clinical and surgical, with better scientific evidence are needed.
Assuntos
Neoplasias Cutâneas/terapia , Xeroderma Pigmentoso/terapia , Antineoplásicos/uso terapêutico , Procedimentos Cirúrgicos Dermatológicos , Fluoruracila/uso terapêutico , Humanos , Imiquimode/uso terapêutico , Pomadas , FotoquimioterapiaRESUMO
BACKGROUND: There are few studies on basal cell carcinoma (BCC) from India. Long-term follow-up is available in only one study and the aesthetic outcome of treatment has not been evaluated in Indian patients. AIMS: In this retrospective study on BCC, we compared treatment failure, recurrence rates and aesthetic outcomes on long-term follow-up between surgical excision and repair, and nonsurgical and ablative treatments. METHODS: Records of patients with BCC treated in the dermatologic surgery clinic over the past 10 years were analyzed. Patients with histopathologically confirmed BCC who could be contacted were evaluated for recurrence, treatment failure, overall satisfaction and aesthetic outcomes by global aesthetic improvement scale. RESULTS: Out of 98 patients, 72 were contactable. Four patients received both nonsurgical and ablative treatments and surgical excision and repair sequentially and were excluded. The mean age of patients was 57.9 ± 15.8 years (24-90 years) and the male: female ratio was 1.6:1. The most common site involved was the face (72.1%) followed by trunk and scalp, and the most common type of BCC was the pigmented superficial type (33.8%), followed by the pigmented noduloulcerative type (16.2%). There was no significant difference between the groups in the number of high-risk cases. The mean follow-up period was 37.1 ± 31.4 (range, 4-120) months. Fifty one patients were treated with surgical excision and repair, and 17 with nonsurgical and ablative treatments (9-imiquimod, 5-cryotherapy, 4-radiotherapy). Treatment failure was seen in 5 (7.4%) patients, all in the nonsurgical and ablative treatments group (P = 0.0006). Recurrence was seen in 2 (2.9%) patients, both in the surgical excision and repair group (P > 0.05). Mean patient satisfaction was significantly higher with surgical excision and repair, though there was no significant difference in the Global Aesthetic Improvement Scale between the groups. LIMITATIONS: The sample size was low. Only telephonic and pictorial assessments were done where the patient could not come for follow-up. CONCLUSIONS: Surgical excision and repair was associated with better outcomes than nonsurgical and ablative treatments. Treatment failures and adverse events were high with nonsurgical and ablative treatments. The recurrence rate was low.
Assuntos
Carcinoma Basocelular/terapia , Neoplasias Cutâneas/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/uso terapêutico , Crioterapia , Feminino , Humanos , Imiquimode/uso terapêutico , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Satisfação do Paciente , Ablação por Radiofrequência , Estudos Retrospectivos , Adulto JovemAssuntos
Antineoplásicos/uso terapêutico , Neoplasias do Ânus/terapia , Tumor de Buschke-Lowenstein/terapia , Neoplasias do Ânus/patologia , Tumor de Buschke-Lowenstein/patologia , Terapia Combinada , Eletrocirurgia , Feminino , Humanos , Imiquimode/uso terapêutico , Fotoquimioterapia , Adulto JovemRESUMO
BACKGROUND: Studies comparing head-to-head treatment modalities for anogenital warts are lacking. AIM: We sought to compare a short, 8-week course of imiquimod 5% cream to versus the standard 4 week course of podophyllotoxin in the treatment of anogenital warts and to assess factors that may affect response to treatment. METHODS: This was a retrospective cohort study. We reviewed medical files of otherwise healthy patients with a first episode of anogenital warts who were treated with either a short, 8-week course of imiquimod or the standard 4-week course of podophyllotoxin. Inverse probability of treatment weighted (IPTW). Logistic regression was employed to evaluate factors that may affect response to therapy. RESULTS: The study included 347 patients. In patients with lesions on dry, keratinized anatomical sites, the complete clearance rates were 7.6% for imiquimod and 27.9% for podophyllotoxin (P < 0.001). In patients with lesions on moist, partially keratinized sites, no difference between the treatments was revealed. Significant predictors of > 50% reduction in wart area were location of lesions [odds ratio (OR) (95% confidence interval (CI)): 3.6 (1.84-7.08), P = 0.0002] for "partially keratinized" versus "keratinized" sites and treatment used [OR (95% CI): 1.79 (1.08-2.97), P = 0.024] for podophyllotoxin versus imiquimod. LIMITATIONS: The retrospective design of the study was a limitation that we mitigated against with the use of IPTW logistic regression. CONCLUSION: A standard 4 week course of Podophyllotoxin was more effective than an 8-week course of imiquimod only for lesions on keratinized sites. Treatment with podophyllotoxin and location of lesions on partially keratinized sites were independent predictors of >50% reduction in wart area.
Assuntos
Doenças do Ânus/tratamento farmacológico , Condiloma Acuminado/tratamento farmacológico , Imiquimode/uso terapêutico , Podofilotoxina/uso terapêutico , Adjuvantes Imunológicos/uso terapêutico , Adulto , Estudos de Coortes , Feminino , Humanos , Ceratolíticos/uso terapêutico , Masculino , Pomadas , Estudos RetrospectivosAssuntos
Adjuvantes Imunológicos/administração & dosagem , Hiperplasia Epitelial Focal/diagnóstico , Hiperplasia Epitelial Focal/tratamento farmacológico , Imiquimode/administração & dosagem , Linfangiectasia Intestinal/diagnóstico , Linfangiectasia Intestinal/tratamento farmacológico , Administração Tópica , Adolescente , Feminino , Hiperplasia Epitelial Focal/complicações , Humanos , Linfangiectasia Intestinal/complicações , Creme para a Pele/administração & dosagem , Resultado do TratamentoAssuntos
Aminoquinolinas/uso terapêutico , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Herpes Genital/diagnóstico , Herpes Genital/tratamento farmacológico , Adjuvantes Imunológicos/farmacologia , Adjuvantes Imunológicos/uso terapêutico , Aminoquinolinas/farmacologia , Infecções por HIV/complicações , Herpes Genital/complicações , Humanos , Imiquimode , Masculino , Pessoa de Meia-Idade , Pênis/efeitos dos fármacos , Pênis/patologia , Resultado do TratamentoAssuntos
Aminoquinolinas/administração & dosagem , Antineoplásicos/administração & dosagem , Doença de Bowen/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Vulva/patologia , Administração Tópica , Adulto , Doença de Bowen/diagnóstico , Feminino , Humanos , Imiquimode , Neoplasias Cutâneas/diagnóstico , Resultado do Tratamento , Vulva/efeitos dos fármacosAssuntos
Aminoquinolinas/administração & dosagem , Condiloma Acuminado/diagnóstico , Condiloma Acuminado/tratamento farmacológico , Pênis/patologia , Vitiligo/diagnóstico , Vitiligo/tratamento farmacológico , Administração Tópica , Adulto , Condiloma Acuminado/complicações , Humanos , Imiquimode , Masculino , Pênis/efeitos dos fármacos , Vitiligo/complicaçõesAssuntos
Aminoquinolinas/efeitos adversos , Antineoplásicos/efeitos adversos , Linfoma de Zona Marginal Tipo Células B/induzido quimicamente , Linfoma de Zona Marginal Tipo Células B/diagnóstico , Administração Tópica , Idoso de 80 Anos ou mais , Aminoquinolinas/administração & dosagem , Antineoplásicos/administração & dosagem , Humanos , Imiquimode , MasculinoAssuntos
Aminoquinolinas/uso terapêutico , Carcinoma Basocelular/complicações , Carcinoma Basocelular/tratamento farmacológico , Falência Renal Crônica/complicações , Neoplasias Cutâneas/complicações , Neoplasias Cutâneas/tratamento farmacológico , Antineoplásicos/uso terapêutico , Carcinoma Basocelular/patologia , Feminino , Humanos , Imiquimode , Pessoa de Meia-Idade , Neoplasias Cutâneas/patologiaRESUMO
Bowen's disease commonly presents as a solitary asymptomatic plaque involving head and neck region or lower limbs. We present a case of a sixty seven-year-old man with an itchy, oozy, crusted solitary plaque on the right ring finger of eighteen months duration with histopathology consistent with Bowen's disease. The lesion was initially treated with topical 5% imiquimod but due to relapse and inadequate response to a second course, complete surgical excision followed by full thickness skin grafting was done. Recurrence after about 6 months in the form of a small papule adjacent to the initial site was also treated with excision. This report highlights the potential of Bowen's disease to mimic more common dermatoses and a high index of suspicion, supported by histopathology, is required to diagnose and treat it without delay, which in turn may require a multimodality approach. We also reviewed the current literature on the same.
Assuntos
Doença de Bowen/diagnóstico , Dedos/patologia , Neoplasias Cutâneas/diagnóstico , Idoso , Aminoquinolinas/administração & dosagem , Doença de Bowen/tratamento farmacológico , Humanos , Imiquimode , Masculino , Neoplasias Cutâneas/tratamento farmacológico , Resultado do TratamentoAssuntos
Aminoquinolinas/uso terapêutico , Antineoplásicos/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Lúpus Eritematoso Discoide/tratamento farmacológico , Administração Cutânea , Orelha , Feminino , Humanos , Imiquimode , Lábio , Pessoa de Meia-Idade , Resultado do TratamentoAssuntos
Síndrome do Nevo Basocelular/diagnóstico , Adulto , Aminoquinolinas/uso terapêutico , Antineoplásicos/uso terapêutico , Síndrome do Nevo Basocelular/tratamento farmacológico , Síndrome do Nevo Basocelular/genética , Fármacos Dermatológicos/uso terapêutico , Aconselhamento Genético , Humanos , Imiquimode , Isotretinoína/uso terapêutico , MasculinoAssuntos
Carcinoma Basocelular/diagnóstico , Fotoquimioterapia , Transtornos da Pigmentação/diagnóstico , Neoplasias Cutâneas/diagnóstico , Idoso , Aminoquinolinas/administração & dosagem , Carcinoma Basocelular/tratamento farmacológico , Feminino , Humanos , Imiquimode , Transtornos da Pigmentação/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
BACKGROUND: There are numerous therapeutic modalities available for treatment of molluscum contagiosum. However, the ablative modalities are painful and not suitable for children. AIM: We aimed to evaluate and compare the safety and efficacy of 2 of the painless modalities, viz., 5% imiquimod cream and 10% potassium hydroxide (KOH) solution, in the treatment of molluscum contagiosum. METHODS: Out of a total of 40 patients of molluscum contagiosum in the study, 18 patients in the imiquimod group and 19 patients in the KOH group completed the study. The given medication was applied by the patient or a parent to mollusca at night, 3 days per week. Imiquimod was continued till clinical cure; and 10% KOH, till lesions showed signs of inflammation. Assessments of response and side effects were performed at the end of week 4, week 8, and week 12. Significance was tested by Student's t test and Mann-Whitney test. RESULTS: The mean lesion count decreased from 22.39 to 10.75 with imiquimod and from 20.79 to 4.31 with KOH at the end of 12 weeks. We found complete clearance of lesions in 8 (44%) patients with imiquimod and in 8 (42.1%) patients with 10% KOH. Minor side effects were seen in 15 (78.9%) patients on KOH and 10 (55.5%) patients on imiquimod. CONCLUSIONS: The results of this study suggest that both 5% imiquimod cream and 10% KOH solution are equally effective in molluscum contagiosum though KOH has a faster onset of action. However, KOH solution is associated with a higher incidence of side effects.